XENCOR INC

Xencor, Inc. reported its financial results for the third quarter ended September 30, 2026, highlighting progress across its clinical-stage pipeline for cancer and autoimmune diseases. Key updates include compelling clinical data for XmAb819 in advanced clear cell renal cell carcinoma, upcoming presentations for plamotamab in rheumatoid arthritis, and on-track development for TL1A-targeting programs XmAb942 and XmAb412. The company also detailed significant milestones achieved with partners Amgen, Astellas, and Zenas BioPharma, and reported a net income of $39.4 million for the quarter.

Xencor Inc.'s stock recently reached a 52-week high of $32.29, currently trading at $32.83, indicating strong market performance and investor confidence with a 90.61% return over the past year. Truist Securities also raised its price target for Xencor to $29 from $27, maintaining a Buy rating ahead of an important update regarding XmAb819 at the ESMO event. Despite appearing overvalued by InvestingPro, these developments highlight potential growth prospects for the biotech company.